Neurotoxic effects induced by gammahydroxybutyric acid (GHB) in male rats.
Gammahydroxybutyric acid (GHB) is an endogenous constituent of the central nervous system that has acquired great social relevance for its use as a recreational 'club drug'. GHB, popularly known as 'liquid ecstasy', is addictive when used continuously. Although the symptoms associated with acute intoxication are well known, the effects of prolonged use remain uncertain. We examined in male rats the effect of repeated administration of GHB (10 and 100 mg/kg) on various parameters: neurological damage, working memory and spatial memory, using neurological tests, the Morris water maze and the hole-board test. The results showed that repeated administration of GHB, especially at doses of 10 mg/kg, causes neurological damage, affecting the 'grasping' reflex, as well as alteration in spatial and working memories. Stereological quantification showed that this drug produces a drastic neuronal loss in the CA1 hippocampal region and in the prefrontal cortex, two areas clearly involved in cognitive and neurological functions. No effects were noted after quantification in the periaqueductal grey matter (PAG), a region lacking GHB receptors. Moreover, NCS-382, a putative antagonist of GHB receptor, prevented both neurological damage and working- memory impairment induced by GHB. This suggests that the effects of administration of this compound may be mediated, at least partly, by specific receptors in the nervous system. The results show for the first time that the repeated administration of GHB, especially at very low doses, produces neurotoxic effects. This is very relevant because its abuse, especially by young persons, could produce considerable neurological alterations after prolonged abuse.
Pedraza
Carmen
C
Department of Psychobiology, Faculty of Psychology, University of Málaga, Spain. mdpedraza@uma.es
García
Francisca Belén
FB
Navarro
José Francisco
JF
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001567:Benzocycloheptenes / Q000494:pharmacology; D003071:Cognition / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006624:Hippocampus / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D013287:Illicit Drugs / Q000633:toxicity*; D007274:Injections, Intraperitoneal; D008297:Male; D008568:Memory / Q000187:drug effects; D009410:Nerve Degeneration / Q000139:chemically induced* / Q000503:physiopathology / Q000523:psychology; D020258:Neurotoxicity Syndromes / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology / Q000523:psychology; D017397:Prefrontal Cortex / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D051381:Rats; D017208:Rats, Wistar; D011956:Receptors, Cell Surface / Q000187:drug effects; D012018:Reflex / Q000187:drug effects; D012978:Sodium Oxybate / Q000008:administration & dosage / Q000633:toxicity*; D013997:Time Factors
C039403:4-hydroxybutyric acid receptor; D001567:Benzocycloheptenes; D013287:Illicit Drugs; D011956:Receptors, Cell Surface; C066471:NCS 382; D012978:Sodium Oxybate